Why organs age differently: Paul Coletta
Organs can age at different rates because aging does not happen uniformly throughout the body, according to Paul Coletta. His account of Vero’s proteomic assay is best understood as directional rather than diagnostic, with clinical validation still in progress.

Key takeaways
- A whole-body biological age may obscure differences in how individual organs are aging. 0:00
- Coletta describes proteomic organ age as a directional signal, not a diagnosis of disease. 7:11
- The assay infers organ-level patterns from proteins in blood rather than directly examining each organ. 8:11
- Repeated measurement matters because Coletta’s model connects biological signals to intervention and measured response. 12:17
A single age can hide the signal
The starting point is asynchronous aging, according to Coletta. Different organs can become vulnerable at different times, which makes a single whole-body age less useful for the question he cares about most: where might decline be showing up first? That changes the frame from trying to make one biological-age score lower to asking which part of the body deserves closer attention.
“But what we haven't known until very recently is that aging isn't synchronous.”
Paul Coletta, Founder and CEO, Vero Bioscience · 0:12
That distinction matters because organ-level measurement is meant to add resolution, not simply create another longevity score. Managing aging requires identifying the organ aging fastest and then understanding what may be driving it, according to Coletta. In his framework, the practical value comes from narrowing the target for action rather than treating the body as though every system were changing together.
“And so if we want to understand and manage aging, we need to measure it at the organ level and find the organ aging fastest.”
Paul Coletta, Founder and CEO, Vero Bioscience · 22:20
Vero classifies organ health relative to chronological age, according to Coletta. An accelerated organ is older by that comparison, while a resilient organ is younger. Those labels describe the model’s organ-aging assessment. They should not be read as diagnoses of organ disease, a boundary that becomes especially important when translating a compelling score into a health decision. 17:11
Proteins provide a different kind of measurement
Coletta explained the underlying idea through the contrast between DNA and proteins. DNA can describe predisposition, while proteins, in his account, reflect the body’s current function more dynamically. That is why proteomics sits at the center of the organ-level approach he described: the assay uses proteins in blood as signals from biological systems rather than treating inherited information as the whole picture.
“Proteins are real-time reporters of the function and health of the organs, which is are the components of our system,” Coletta said, 2:41
The test itself starts with blood, but Coletta said its output is organized around organs. The model takes proteomic signatures and matches them with people of the same age in the reference cohort. In other words, the organ-age result is not a direct look inside an organ. It is an inference built from circulating protein patterns and comparisons within the model. 8:11
Predictive does not mean diagnostic
This is the most important boundary in the conversation. Vero’s assay does not diagnose anything, according to Coletta. He contrasted it with tests designed to find a current state of disease or dysfunction, describing this system instead as predictive. That wording matters because an organ-age result should not be treated as proof that someone has a disease, or as a replacement for clinical diagnosis.
Coletta explained the predictive concept through comparison with outcomes in the reference population. The model looks at what happened to people whose proteomic signatures resembled the person being tested. That makes the output fundamentally about modeled future risk and biological direction. It does not establish what will happen to an individual, and the conversation does not provide evidence for a specific level of diagnostic accuracy. 8:11
That caution is not external to Coletta’s pitch. Coletta said the company does not want to get ahead of clinical validation, and he said work as still in progress. For fitness and wellness operators, that is a useful line to hold: the interesting idea is more precise biological feedback, but the transcript does not support presenting the assay as an established diagnostic tool.
“We want to, we don't want to get ahead of the science in this clinical validation,” Coletta said, 30:42
The bigger idea is closing the feedback loop
Measurement alone is not the end goal, Coletta said. His model connects health data to targeted action and then measures the response, creating a feedback loop rather than a one-time report. That gets closer to the real opportunity for fitness: information becomes more useful when it can help shape an intervention and then show whether the measured biology moved afterward. 12:17
If the measured response does not move in the desired direction, The system can try another approach, Coletta said. The point is iteration based on the individual rather than assuming one intervention works equally well for everyone. That is a meaningful distinction from simply collecting more health metrics, because the value proposition shifts toward learning from repeated measurement instead of accumulating another static dashboard.
Direction is the useful frame
Coletta described the future he is building toward as directional rather than diagnostic. That is probably the cleanest way to understand the entire conversation. Broad age measures give one summary signal, while his organ-level approach aims to identify where biology may be moving differently and provide a target for follow-up. The promise is better direction, not certainty about disease.
Coletta said Vero is being built with a clinician in the loop, even when artificial intelligence supports the process. That positioning reinforces the right interpretation of organ-level data: a potentially useful input for understanding patterns and guiding action, not an autonomous verdict about somebody’s health. Better measurement only becomes valuable when people know what it can and cannot tell them. 13:17
Explore the Longevity and Science topic hub for more source-backed conversations.
Listen to the full conversation
The New Science of Aging: Why Your Organs Age at Different Rates with Paul Coletta
Play the episodeFrequently asked questions
What does it mean for organs to age at different rates?
Coletta added that aging is not synchronous, meaning different organs may become vulnerable at different times. His framework therefore separates organ-level aging from a single broad measure of biological age and focuses attention on where aging may appear more accelerated relative to the rest of the body. 0:00
What does proteomics measure in organ aging?
Coletta added that proteins act as real-time reporters of organ function and health. In the approach he outlined, protein signatures found in blood become inputs for models that estimate organ-level aging patterns, giving the test a different role from genetic information centered on predisposition. 1:56
Can an organ-age test diagnose disease?
No, not according to Coletta’s description of Vero’s assay. Coletta explicitly said the assay does not diagnose anything. He presented it as predictive and directional, which means its organ-aging output should not be interpreted as confirmation that a person currently has a particular disease. 7:11
Is Vero's organ-aging assay clinically validated?
Coletta detailed that clinical validation remained in progress at the time of the conversation. He also stated the company did not want to get ahead of that work. So the transcript supports describing the approach and its intended use, but not claiming established diagnostic accuracy or completed clinical validation. 30:40
Related insights
Quotes are lightly edited for clarity.
